

# Research Grade Lintuzumab

## Summary

---

<b>Catalog No.</b>	DHD37502
<b>Alternative Names</b>	225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
<b>Clone ID</b>	Lintuzumab
<b>Host species</b>	Humanized
<b>Species reactivity</b>	Human
<b>Form</b>	Liquid
<b>Storage buffer</b>	0.01M PBS, pH 7.4.
<b>Concentration</b>	1.39 mg/ml
<b>Purity</b>	>95% as determined by SDS-PAGE.
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1-kappa
<b>Applications</b>	Research Grade Biosimilar
<b>Target</b>	Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
<b>Purification</b>	Protein A/G purified from cell culture supernatant.
<b>Endotoxin level</b>	Please contact with the lab for this information.
<b>Expression system</b>	Mammalian Cells
<b>Accession</b>	P20138

**Stability and Storage**

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.


**Note**

For research use only. Not suitable for clinical or therapeutic use.

## Description


Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).

## Data Image




SDS-PAGE

SDS PAGE for Lintuzumab



Detects CD33 in indirect ELISAs.

### Bioactivity



The purity of this product is >95% as determined by SEC-HPLC.

### SEC-HPLC